Other actionable mutations occur in PIK3CA, IDH1, ERBB4, PREX2, EGFR, CDK4, MET, and PPP6C. Mutated ERBB4, EGFR, CDK4, PIK3CA, IDH1, and MET are well-established therapeutic targets in various cancers, including breast (Hunter et al. 2023), CDK4), lung (Zubair and Bandyopadhyay 2023), EGFR), (Mathieu et al. 2022), MET), lymphomas (Yu et al. 2023), PIK3CA), and leukemia (Chen et al. 2023), IDH1), however, their inhibitors are not yet recognized in melanoma treatment. This evidence concerns the gene MET and cancer.